Pramana
Immuno-metabolism
Driving development of our lead candidate and novel small molecule platform that acts as a "glucose rheostat". We believe robust glucose control is the key to treating disease states. We are committed to enable better long term treatment options for patients.
We are advancing a broad pipeline of biologic drug candidates. Our vast library of Novel potent and selective GPCR agonists was discovered and optimized in-house....by a team that has discovered many important drugs.
Pramana
490,000,000,000
Dollars in Global Healthcare Expenditures of Diabetes by 2030
537,000,000
People currently live with diabetes
1,000,000,000+
People will suffer from diabetes by 2050
The unmet opportunity - Pramana's commitment
The opportunity for an Oral Preventative Treatment for Hypoglycemia is just one of many areas of high unmet medical need associated with Metabolic Disorders. We are committed to addressing this.
100,000,000
People living with Diabetes may be misdiagnosed and affected by Latent Autoimmune Diabetes in Adults right now
The opportunity to treat Latent Autoimmune Diabetes in adults is an area of high unmet medical need associated with Immunometabolic disorders. We are committed to addressing this.